According to a new report LAMEA Companion Diagnostics Market, published by KBV research, the LAMEA Companion Diagnostics Market would witness market growth of 20.7% CAGR during the forecast period (2019-2025).
The Brazil market dominated the LAMEA Polymerase chain reaction (PCR) Market by Country in 2018, growing at a CAGR of 20.2 % during the forecast period. The Argentina market is expected to witness a CAGR of 22.5% during (2019 - 2025). Additionally, The UAE market is expected to witness a CAGR of 20.5% during (2019 - 2025).
The Oncology market dominated the Saudi Arabia Companion Diagnostics Market by Indication in 2018, growing at a CAGR of 22.3 % during the forecast period. The Neurology market is expected to witness a CAGR of 19.4% during (2019 - 2025).
The Breast Cancer market dominated the Nigeria Companion Diagnostics Market by Cancer Type in 2018, growing at a CAGR of 22.9 % during the forecast period. The Colorectal Cancer market is expected to witness a CAGR of 23.6% during (2019 - 2025).
Full Report:https://www.kbvresearch.com/lamea-companion-diagnostics-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Agilent Technologies, Inc., Almac Group, ARUP Laboratories, Inc., Abbott Laboratories (Abbott Laboratories Molecular, Inc.), Danaher Corporation, Thermo Fisher Scientific, Inc., Hologic, Inc., Novartis AG, Illumina, Inc., Qiagen N.V.
By Technology
By Indication
By Cancer Type
By Country
Companies Profiled
Unique Offerings from KBV Research
Unique Offerings 
